# Celldex Therapeutics, Inc.: overview

CLDX · Nasdaq · CIK 744218 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cldx.md) · [Financials](/companies/cldx/financials.md) · [Filings](/companies/cldx/filings.md) · [Insiders](/companies/cldx/insiders.md)

Latest reported revenue: [$22.0k](/filings/0001104659-26-091984.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-091984).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.2](/filings/0001104659-25-109137.md) | [1.2 d](/filings/0001104659-26-019652.md) | [0.7](/filings/0001104659-26-057113.md) | [0.7](/filings/0001104659-26-091984.md) | [0.0 d](/filings/0001104659-25-109137.md) | [0.1 d](/filings/0001104659-26-019652.md) | [0.0](/filings/0001104659-26-057113.md) | [0.0](/filings/0001104659-26-091984.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(1633.5%)](/filings/0001104659-25-109137.md) | [(4768.3%) d](/filings/0001104659-26-019652.md) | [(9027.2%)](/filings/0001104659-26-057113.md) | [(8747.5%)](/filings/0001104659-26-091984.md) | not reported | [(72027.3%) d](/filings/0001104659-26-019652.md) | [(562900.0%)](/filings/0001104659-26-057113.md) | [(366468.2%)](/filings/0001104659-26-091984.md) |
| Net margin | % | [(1320.0%)](/filings/0001104659-25-109137.md) | [(4007.8%) d](/filings/0001104659-26-019652.md) | [(7740.4%)](/filings/0001104659-26-091984.md) | [(7753.4%)](/filings/0001104659-26-091984.md) | not reported | [(67204.1%) d](/filings/0001104659-26-019652.md) | [(524566.7%)](/filings/0001104659-26-091984.md) | [(334104.5%)](/filings/0001104659-26-091984.md) |
| Diluted EPS | $ per share | [(0.64)](/filings/0001104659-25-109137.md) | not reported | [(0.81)](/filings/0001104659-26-057113.md) | [(0.85)](/filings/0001104659-26-091984.md) | [(1.01)](/filings/0001104659-25-109137.md) | not reported | [(1.18)](/filings/0001104659-26-057113.md) | [(0.94)](/filings/0001104659-26-091984.md) |
| Free cash flow | $m | [(55.9) d](/filings/0001104659-25-109137.md) | [(33.2) d](/filings/0001104659-26-019652.md) | [(54.6)](/filings/0001104659-26-057113.md) | [(44.7) d](/filings/0001104659-26-091984.md) | [(49.1) d](/filings/0001104659-25-109137.md) | [(65.2) d](/filings/0001104659-26-019652.md) | [(67.2)](/filings/0001104659-26-057113.md) | [(60.6) d](/filings/0001104659-26-091984.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.7](/filings/0001410578-24-000076.md) | [2.4](/filings/0001410578-25-000216.md) | [6.9](/filings/0001104659-26-019652.md) | [7.0](/filings/0001104659-26-019652.md) | [1.5](/filings/0001104659-26-019652.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(1531.8%)](/filings/0001410578-24-000076.md) | [(4889.0%)](/filings/0001410578-25-000216.md) | [(2245.3%)](/filings/0001104659-26-019652.md) | [(2778.9%)](/filings/0001104659-26-019652.md) | [(18599.8%)](/filings/0001104659-26-019652.md) |
| Net margin | % | [(1516.0%)](/filings/0001410578-24-000076.md) | [(4765.6%)](/filings/0001410578-25-000216.md) | [(2054.8%)](/filings/0001104659-26-019652.md) | [(2248.8%)](/filings/0001104659-26-019652.md) | [(16748.0%)](/filings/0001104659-26-019652.md) |
| Diluted EPS | $ per share | [(1.64)](/filings/0001410578-24-000076.md) | [(2.40)](/filings/0001410578-25-000216.md) | [(2.92)](/filings/0001104659-26-019652.md) | [(2.45)](/filings/0001104659-26-019652.md) | [(3.90)](/filings/0001104659-26-019652.md) |
| Free cash flow | $m | [(62.2)](/filings/0001410578-24-000076.md) | [(106)](/filings/0001410578-25-000216.md) | [(109)](/filings/0001104659-26-019652.md) | [(160)](/filings/0001104659-26-019652.md) | [(214)](/filings/0001104659-26-019652.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cldx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $355.1m | 9,543,671 |  | Added +983,195 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $260.6m | 7,002,530 |  | Added +1,632,645 |
| [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $198.1m | 5,322,908 |  | Reduced −517,659 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $145.1m | 3,900,427 |  | Added +1,096,259 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $138.5m | 3,722,888 |  | Reduced −26,160 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $128.9m | 3,464,831 |  | Added +503,936 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $109.4m | 2,939,151 |  | Added +1,655,172 |
| [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $78.1m | 2,100,000 |  | Added +1,650,000 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $75.3m | 2,022,226 |  | Added +334,152 |
| [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $66.5m | 1,785,941 |  | Reduced −2,075 |

## Recent filings

[All 891 filings](/companies/cldx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-22 | 11:09 ET | [8-K](/filings/0001104659-26-109465.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-109465 |
| 2026-08-06 | 20:06 ET | [10-Q](/filings/0001104659-26-091984.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091984 |
| 2026-08-06 | 20:01 ET | [8-K](/filings/0001171843-26-005316.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005316 |
| 2026-07-15 | 20:07 ET | [8-K](/filings/0001104659-26-083880.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-083880 |
| 2026-06-26 | 12:43 ET | [8-K](/filings/0001104659-26-078023.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-078023 |
| 2026-05-07 | 20:07 ET | [10-Q](/filings/0001104659-26-057113.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057113 |
| 2026-05-07 | 20:01 ET | [8-K](/filings/0001171843-26-003153.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-003153 |
| 2026-04-29 | 12:00 ET | [DEF 14A](/filings/0001104659-26-050884.md) | Proxy statement, period 2026-06-25 | 0001104659-26-050884 |
| 2026-04-02 | 12:08 ET | [8-K](/filings/0001104659-26-038882.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-038882 |
| 2026-02-25 | 21:06 ET | [10-K](/filings/0001104659-26-019652.md) | Annual report, period 2025-12-31 | 0001104659-26-019652 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-019652.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/661af4f3-ac1b-42b8-9250-11be29ce4b35)

## About the filer

- CIK: 744218
- Tickers: CLDX
- Exchange: Nasdaq
- SIC code: 2835 In Vitro & In Vivo Diagnostic Substances
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.